Europe Cardiovascular Surgical Devices market USD 762.66 million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.3% from 2024 to 2031. Aging population, high prevalence of cardiovascular diseases, and advanced healthcare infrastructure is expected to aid the sales to USD 937.4 million by 2031

Snapshot img

Cardiovascular Medical Devices Market Size 2024-2028

The cardiovascular medical devices market size is forecast to increase by USD 19.08 billion at a CAGR of 7.2% between 2023 and 2028.

The market is witnessing significant growth due to the increasing prevalence of cardiac conditions such as atrial fibrillation and clogged arteries. This trend is driven by the rising number of individuals with these conditions and the growth of insurance providers covering diagnostic monitoring devices. companies in this market are focusing on innovative technologies like Al and machine learning based electrocardiogram (ECG) technology to improve the accuracy and efficiency of cardiovascular diagnosis. Surgical devices, including ECG, Holter monitors, event monitors, and implantable loop recorders, are essential tools for the early detection and treatment of cardiovascular diseases. However, the high cost of cardiovascular procedures remains a challenge for market growth. To stay competitive, companies must offer cost-effective solutions while maintaining the highest standards of quality and patient safety. This market analysis report provides a comprehensive overview of the market growth factors, business strategies, and challenges shaping the future of the cardiovascular medical devices industry.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

The market holds significant importance in the healthcare industry as these devices play a crucial role in diagnosing, monitoring, and treating various heart disorders. Heart diseases, including heart failure, cardiomyopathy, and stroke, are fatal conditions that pose a major health concern worldwide. According to the World Health Organization (WHO), cardiovascular diseases accounted for approximately 17.9 million deaths in 2016. Minimally invasive procedures and advanced cardiovascular devices have revolutionized the treatment landscape, offering improved patient outcomes and reduced healthcare resources. Diagnostic monitoring devices, such as ECG and Holter monitors, enable early detection and timely intervention, thereby reducing the risk of complications and mortality.
In addition, cardiology devices, including coronary artery stents and surgical devices, have significantly contributed to the advancement of cardiovascular care. For instance, coronary artery stents help in the treatment of coronary artery diseases by improving blood flow and reducing the risk of heart attacks. Artificial intelligence (AI) is increasingly being integrated into cardiovascular devices to enhance their functionality and accuracy. AL-based ECG technology, for example, can analyze ECG data more efficiently and accurately than traditional methods, enabling early detection and diagnosis of heart conditions. The cardiovascular devices market is expected to witness steady growth due to the increasing prevalence of heart disorders and the need for advanced diagnostic and therapeutic solutions.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Product

  Diagnostic and monitoring systems
  Surgical devices


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France
    Italy


  Asia

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

By Product Insights

The diagnostic and monitoring systems segment is estimated to witness significant growth during the forecast period.

The diagnostic and monitoring segment of the international market comprises various devices that play a vital role in evaluating heart health, identifying cardiovascular diseases (CVDs) in their initial stages, and tracking disease progression or treatment response. This segment includes devices like ECGs, which measure the electrical activity of the heart and are crucial for diagnosing arrhythmias, heart attacks, and other cardiac conditions. Furthermore, echocardiograms, which employ ultrasound technology to generate detailed images of the heart, aid in assessing structural heart diseases and evaluating heart function. Portable ECG devices, such as Holter monitors and event monitors, are also part of this segment. These devices enable continuous heart monitoring over extended durations, allowing doctors to detect irregularities that may not surface during routine ECG tests.

Get a glance at the market report of share of various segments Request Free Sample

The diagnostic and monitoring systems segment was valued at USD 21.14 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 38% to the growth of the global market during the fore

The Europe Cardiac Arrhythmia Monitoring Devices Market report segments the industry into Devices (Event Monitoring Devices, Continuous Rhythm Monitoring Devices, Holter Monitoring Devices, Other Devices), Service Providers (Mobile Cardiac Telemetry Monitoring Service Providers, Independent Diagnostic Testing Facilities/Clinics), and Geography (Germany, United Kingdom, France, Italy, Spain, Rest of Europe).

The global cardiovascular devices market, valued at $58.89 billion in 2025, is projected to experience robust growth, driven by a rising prevalence of cardiovascular diseases, an aging global population, and technological advancements leading to the development of minimally invasive procedures and sophisticated devices. The market's Compound Annual Growth Rate (CAGR) of 4.97% from 2025 to 2033 indicates a significant expansion, with substantial contributions anticipated from both diagnostic and therapeutic devices. The diagnostic segment, encompassing devices like electrocardiograms (ECGs) and cardiac monitors, benefits from increased screening and early detection initiatives. Therapeutic devices, including stents, pacemakers, and heart valves, are witnessing growth fueled by the increasing demand for effective treatment options and improved patient outcomes. Technological advancements, such as the integration of artificial intelligence and big data analytics in device design and patient management, further contribute to market expansion. Regional variations exist, with North America and Europe currently holding significant market shares due to well-established healthcare infrastructure and high healthcare expenditure. However, the Asia-Pacific region is anticipated to show faster growth in the coming years due to rising awareness, improving healthcare infrastructure and increasing disposable incomes. Growth might be slightly tempered by factors such as stringent regulatory approvals and high device costs, particularly in developing economies. The competitive landscape is characterized by the presence of several established players, including Siemens Healthcare, Medtronic, and Abbott, alongside emerging companies focused on innovation and technological advancements. These companies are actively engaged in research and development, seeking to enhance device efficacy, safety, and affordability. Strategic partnerships, mergers, and acquisitions will continue to shape the market dynamics as companies aim to expand their product portfolios and market reach. The market segmentation by device type (diagnostic and therapeutic) and by region allows for focused market analysis and strategic planning for companies seeking to optimize their market position and capture a larger share of this expanding market. The increasing demand for minimally invasive procedures and preference for advanced technologies will continue to drive innovation and growth within this vital sector of the healthcare industry. Recent developments include: October 2022: Medtronic plc received United States FDA approval for expanded labeling of a cardiac lead that taps into the heart's natural electrical system, giving patients needed therapy while avoiding complications sometimes associated with traditional pacing methods, such as cardiomyopathy., October 2022 : Biosense Webster, Inc., part of Johnson & Johnson MedTech launched the HELIOSTAR Balloon Ablation Catheter in Europe. The HELIOSTAR Balloon Ablation Catheter is indicated for use in the catheter-based cardiac electrophysiological mapping (stimulating and recording) of the atria and, when used with a compatible multi-channel RF generator, for cardiac ablation.. Key drivers for this market are: Rapid Technological Advancements, Increasing Burden of Cardiovascular Diseases; Increased Preference for Minimally Invasive Procedures. Potential restraints include: Stringent Regulatory Policies and Product Recalls, High Cost of Instruments and Procedures. Notable trends are: The Electrocardiogram (ECG) Under Diagnostic and Monitoring Devices Segment is Expected to Hold a Significant Share in the Market.

According to Cognitive Market Research, the Cardiovascular Devices Market Size will be USD XX Billion in 2024 and is set to achieve a market size of USD XX Billion by the end of 2033 growing at a CAGR of XX% from 2025 to 2033.

• North America held largest share of XX% in the year 2024 • Europe held share of XX% in the year 2024 • Asia-Pacific held significant share of XX% in the year 2024 • South America held significant share of XX% in the year 2024 • Middle East and Africa held significant share of XX% in the year 2024

Market Dynamics of the Cardiovascular Devices Market Key Drivers for the Cardiovascular Devices Market

Rising in cardiovascular diseases prevalence fuels the cardiovascular devices market 

The cardiovascular disorders are the group of medical condition where it affects heart and blood vessels, encompassing various diseases and disorder that affects on the circulatory system. The cardiac devices help to maintain the regular heart function and blood flow in patients with weak improper function of heart. The global cardiac device market shows significant growth, largely driven by increase in prevalence of heart disease. The cardiovascular disease treatment is costly in terms of healthcare services. Now the conditions like coronary artery disease and heart failure are becoming increasingly prevalent, so there is increase in demand of coronary stents and crucial devices which are used to treat the cardiovascular diseases. Also, the global population increases and continues to age the incidence of chronic heart condition is expected to rise. This demographic condition is shift further and results in growing need of cardiovascular devices that can treat the wide range of heart diseases. For instance, according to centers for disease control and prevention (CDC) in the United States heart diseases is the major cause of death for both men and women and people of most racial and ethnic groups. They said that one person dies every 33 seconds from cardiovascular disease. In 2022, 702,880 people died from heart disease. That is equivalent to 1 in every 5 deaths (Source - https://www.cdc.gov/heart-disease/index.html ) Thus, due to the rising patients in cardiovascular disease segment and the advancement in technology boosts the cardiovascular devices market. Rising awareness of health also helps to drive this market.

The rise in healthcare expenditure drives the Cardiovascular Devices Market

Globally the health awareness is increasing vastly countries monitor their health of the population related to cardiac health preferably. They also focus on the expansion of healthcare expenditure where the people also now get aware about their health. The advancement in technology of medical devices increases the patient convenience and now they can get treatment and monitor their health more effectively. Each country now spends on their healthcare expenditure to provide healthcare service to all needy people who cannot afford the costly devices. For instance, U.S. health expenditure grew by 4.1% in 2022 to $4.5 trillion or $13,493 per capita. This rate of growth is similar to pre-pandemic levels (4.1% in 2019). While government expenditure to contain the pandemic resulted in significant growth in NHE, these expenditures fell sharply in 2021 while use of medical goods and services recovered. By 2022, overall trends in health expenditure more closely approximated that of the pre-pandemic era. (Source - https://www.ama-assn.org/about/research/trends-health-care-spending ) The market for cardiovascular devices is expected to grow as a result of rising healthcare costs. The total amount spent on healthcare-related services, goods, and activities over a given time period usually at the individual, community, national, or international level is referred to as healthcare expenditures. Adoption of cutting-edge cardiovascular technologies and devices is made possible by increased healthcare spending, which improves patient outcomes and care. For Instance, in Europe the spending on cardiovascular disease is greater than the spending done in Germany. CVD is estimated to cost the EU €282 billion annually, with health and long-term care accounting for €155 billion (55%), equaling 11% of EU-health exp...

The size of the Spain Cardiovascular Devices Industry was valued at USD 1.1 billion in 2023 and is projected to reach USD 1.7 billion by 2032, with an expected CAGR of 4.50% during the forecast period. The Spain Cardiovascular Devices Industry mainly concerns with devices that are used for diagnosing, preventing, treating and managing Cardiovascular diseases. Some of the major products offered are stents, pacemakers, defibrillators, heart valves, ECG and echocardiography equipment among others. Some of the trends include innovations in less invasive treatments including TAVR and coronary angioplasty, and the expansion of digital health and remote monitoring solutions all running through an increasingly advanced technology platform. It is thus driven by several factors including the high incidence of cardiac ailments; growth in population of the elderly; and enhancement in the understanding of heart problems. Further, growth of market can be attributed to factors like sound Spanish healthcare system, investment in evolution of medical technology and favourable trade policies. The quest for improving patients’ status and increasing the utilization of sophisticated cardiovascular care is another driving factor for the market growth. Recent developments include: October 2022- Global Instrumentation LLC received CE Mark certification for the M5 Wearable ECG Recorder. The CE mark will allow the company to engage in the next steps of the country-specific entrance of the product into the European Union (EU)., April 2022- Venus Medtech announced that its in-house developed innovative transcatheter pulmonic valve replacement (TPVR) system VenusP-Valve received CE marking under the Medical Devices Regulation (MDR), which is to be marketed across Europe.. Key drivers for this market are: Rapid Technological Advances to Boost the Market Growth, Increasing Prevalence of Cardiovascular Diseases in Spain. Potential restraints include: High Cost of Devices and Procedures. Notable trends are: Electrocardiogram (ECG) is Expected to Hold a Significant Share of the Market Over the Forecast Period.

The Europe Cardiac Rhythm Management Devices Market report segments the industry into By Product (Defibrillators, Pacemakers, Cardiac Resynchronization Therapy Devices) and By Geography (Germany, United Kingdom, France, Italy, Spain, Rest of Europe). Get five years of historical data and market forecasts.

The global cardiovascular medical devices market is experiencing robust growth, driven by an aging population, rising prevalence of cardiovascular diseases (CVDs), and technological advancements leading to improved diagnostic and therapeutic options. The market, estimated at $50 billion in 2025, is projected to exhibit a Compound Annual Growth Rate (CAGR) of 6% from 2025 to 2033, reaching an estimated value of approximately $80 billion by 2033. Key growth drivers include increasing investments in healthcare infrastructure, particularly in emerging economies, expanding access to minimally invasive procedures, and the development of innovative devices such as advanced cardiac rhythm management systems and sophisticated interventional cardiac devices. The market is segmented by application (hospitals, clinics, and others) and device type (cardiac rhythm management devices, interventional cardiac devices, cardiac prosthetic devices, and others). Hospitals currently represent the largest segment due to the complex nature of cardiovascular procedures and the availability of advanced medical infrastructure. However, the clinics segment is expected to witness significant growth driven by the increasing preference for outpatient procedures. Major players like Medtronic, Abbott, Boston Scientific, and Edwards Lifesciences dominate the market, leveraging their strong research and development capabilities, extensive distribution networks, and established brand reputations. However, increasing competition from emerging market players and the potential for consolidation within the industry will continue to shape the market landscape. While technological advancements represent a significant driver, regulatory hurdles, high device costs, and potential reimbursement challenges pose restraints to market growth. Regional variations exist, with North America and Europe currently holding the largest market shares, reflecting higher healthcare expenditure and technological advancements. However, significant growth is anticipated in Asia Pacific, driven by rising healthcare awareness, economic development, and an expanding middle class. The ongoing focus on improving patient outcomes and reducing healthcare costs will be crucial factors determining the future trajectory of the cardiovascular medical devices market.

The global cardiac medical devices market is experiencing robust growth, driven by an aging population, rising prevalence of cardiovascular diseases, technological advancements leading to minimally invasive procedures, and increasing healthcare expenditure. The market's expansion is fueled by innovations in implantable cardioverter-defibrillators (ICDs), pacemakers, cardiac rhythm management (CRM) devices, and minimally invasive cardiac surgery tools. Demand for advanced diagnostic imaging technologies like echocardiography and cardiac CT scans also contributes to market growth. While regional variations exist, North America and Europe currently hold significant market share due to established healthcare infrastructure and high adoption rates of advanced medical technologies. However, the Asia-Pacific region is projected to witness the fastest growth in the coming years, driven by rising disposable incomes, improving healthcare access, and increasing awareness of cardiovascular health. Growth is also influenced by factors like favorable reimbursement policies and government initiatives promoting preventative healthcare. Competition among established players like Medtronic, St. Jude Medical, Boston Scientific, and LivaNova, along with emerging market entrants, is intensifying, leading to increased innovation and improved device affordability. Challenges include stringent regulatory approvals, high device costs, and the potential for complications associated with implanted devices. Nevertheless, the long-term outlook for the cardiac medical devices market remains positive, with continuous growth predicted throughout the forecast period. The market segmentation reveals significant opportunities within specific device types and applications. For instance, the demand for advanced pacemakers and ICDs with remote monitoring capabilities is increasing, while the growth of minimally invasive procedures is driving demand for smaller, more sophisticated surgical tools. Furthermore, technological advancements are leading to improved device longevity and reduced complications, thus positively impacting market growth. The continued focus on improving patient outcomes and reducing healthcare costs through better device technology and efficient treatment protocols are key driving forces. While certain regions show faster growth than others, the overall market is poised for substantial expansion, presenting considerable investment potential for stakeholders across the value chain. The continued rise in cardiovascular diseases worldwide will necessitate a constant stream of technological innovations and improved access to advanced cardiac care, further driving market expansion.

The interventional cardiovascular device market is experiencing robust growth, driven by an aging global population, rising prevalence of cardiovascular diseases, technological advancements leading to minimally invasive procedures, and increasing healthcare expenditure. The market, estimated at $50 billion in 2025, is projected to exhibit a compound annual growth rate (CAGR) of 7% from 2025 to 2033. This growth is fueled by several key trends, including the adoption of sophisticated imaging systems for precise diagnosis and treatment, the development of biocompatible and drug-eluting stents, and the increasing demand for minimally invasive procedures that reduce patient recovery time and hospital stays. Furthermore, the expansion of healthcare infrastructure in emerging economies and rising disposable incomes in these regions are contributing significantly to market expansion. However, certain restraints are hindering market growth. These include the high cost of advanced interventional devices, stringent regulatory approvals, potential complications associated with procedures, and the presence of alternative treatment modalities. Market segmentation reveals strong growth in imaging systems and advanced stents, while the hospital segment remains the dominant application area. Leading companies such as Boston Scientific, Abbott Laboratories (Cordis), and Medtronic are actively investing in research and development, strategic acquisitions, and geographic expansion to maintain a competitive edge in this lucrative market. The geographical distribution shows North America and Europe currently holding the largest market share, although the Asia-Pacific region is anticipated to demonstrate significant growth potential in the coming years due to increasing awareness of cardiovascular diseases and improved healthcare access.

The size of the Italy Cardiovascular Devices Market was valued at USD 65.53 Million in 2023 and is projected to reach USD 117.68 Million by 2032, with an expected CAGR of 4.50% during the forecast period. The Italy cardiovascular devices market encompasses the tools and systems that are applied for diagnosing the cardiovascular disorders and for their treatment, including monitoring their condition. Relating to the kinds of devices, these can be as follows: Stents, pacemakers, defibrillators, heart valves, and vascular grafts and have significant significance in treatment of ailments such as CAD, heart failure, and arrhythmias. Growth will be supported by factors such as rising population and ageing, higher incidence of cardiovascular diseases and development of minimally invasive surgeries. Some of the emerging trends are thus are the catheter-based intervention, advancement in imaging and monitoring systems, application of Artificial intelligence in diagnosis, treatment. The rise in the adoption of technologically advanced solutions in healthcare by Italy and continuously rising healthcare spent in this region also fuels this market. Recent developments include: August 2022: Medtronic launched the latest generation of drug-eluting coronary stent systems following CE Mark approval in European countries., April 2022: Translumina launched its Dual Drug Polymer-Free Coated Stent named VIVO ISAR in the European market, including Italy.. Key drivers for this market are: Increasing Burden of Cardiovascular Diseases Coupled with Rising Geriatric Population, Rapid Technological Advancements and the Increased Preference for Minimally Invasive Procedures. Potential restraints include: Stringent Regulatory Policies and High Cost of Instruments and Procedures. Notable trends are: Stents are Expected to Witness Significant Growth Over the Forecast Period..

Dive into Market Research Intellect's Cardiovascular Devices Market Report, valued at USD 50.3 billion in 2024, and forecast to reach USD 75.2 billion by 2033, growing at a CAGR of 5.5% from 2026 to 2033.

The European cardiac monitoring market, valued at €6.31 billion in 2025, is projected to experience robust growth, driven by a rising geriatric population susceptible to cardiovascular diseases, increasing prevalence of heart failure and arrhythmias, technological advancements in device miniaturization and remote monitoring capabilities, and rising healthcare expenditure. The market's Compound Annual Growth Rate (CAGR) of 4.82% from 2025 to 2033 indicates sustained expansion. Growth is further fueled by the increasing adoption of minimally invasive procedures, improved diagnostic accuracy of cardiac monitoring devices, and the growing preference for home-based cardiac monitoring, reducing hospital readmissions and improving patient outcomes. The segment comprising implantable loop recorders, pacemakers, and defibrillators is expected to dominate due to their critical role in managing life-threatening cardiac conditions. However, high initial costs associated with these devices and stringent regulatory approvals pose challenges to market expansion. Germany, France, and the United Kingdom are anticipated to be the largest markets within Europe, reflecting their advanced healthcare infrastructure and significant patient populations. Competition among established players like Medtronic, Boston Scientific, and Philips, alongside emerging innovative companies, intensifies the market dynamics. The market segmentation reveals a strong emphasis on advanced device types. Implantable loop recorders, offering continuous monitoring for extended periods, are gaining traction. Smart wearable devices are also gaining market share due to their convenience and remote monitoring capabilities. The end-user segment dominated by hospitals and clinics is expected to maintain its prominent position, although home care settings are anticipated to witness significant growth fueled by technological advancements and a shift towards personalized healthcare. The forecast period of 2025-2033 anticipates continued market expansion, largely driven by ongoing technological innovations, favorable reimbursement policies, and the increasing awareness of early detection and management of cardiovascular diseases. Further expansion is likely due to ongoing research and development in areas such as artificial intelligence-driven diagnostics and personalized medicine applications within cardiac monitoring technology. Recent developments include: November 2022: Boston Scientific announced the European launch of the LUX-Dx insertable cardiac monitor (ICM) system, a long-term diagnostic device inserted under the skin of patients to detect arrhythmias associated with conditions such as Atrial Fibrillation (AF), cryptogenic stroke, and syncope., November 2022: Heart experts at University Hospital Southampton (UHS) implanted a new leadless pacemaker defibrillator system to treat patients at risk of sudden cardiac arrest. The surgery is a component of a global clinical trial involving the implantation of the innovative leadless pacemaker EMPOWER and the Subcutaneously Implanted Cardioverter-Defibrillator (S-ICD).. Key drivers for this market are: Growing Incidences of Cardiovascular Diseases, Technological Advancements in the Cardiac Monitoring Products; Demand for Home-based, Point of Care, and Remote Monitoring Cardiac Systems. Potential restraints include: Risk of Infection due to Implantable Monitoring Devices, Unfavorable Reimbursement Policies. Notable trends are: ECG Monitor Segment is Expected to Dominate the Cardiac Monitoring Market During the Forecast Period.

The size of the Netherlands Cardiovascular Devices Market was valued at USD 686.27 Million in 2023 and is projected to reach USD 1003.61 Million by 2032, with an expected CAGR of 5.58% during the forecast period. The Netherlands Cardiovascular Devices Market comprises of an assortment of devices used for diagnosis, treatment and monitoring of cardiovascular disorders. This ranges from stents to pacemakers, defibrillators and catheter based interventions to include laboratory tests . These devices are used in the management of diseases such as coronary artery disease, heart failure as well as irregular heart rhythms. These include uses such as interventions that are less invasive, heart valves replacements, as well as monitoring. Some of the current trends witnessed in the Netherlands are the use of sophisticated wearable cardiac monitors, application of digital health solutions and a patient-centered design. The factors that are driving the market growth include rising the population, high incidence of cardiovascular diseases or conditions, and technological improvements with the device. Recent developments include: August 2022: Medtronic launched a drug-eluting coronary stent, the Onyx Frontierdrug-eluting stent (DES), following recent CE Mark approval. The Onyx Frontier DES offers an innovative delivery system and builds upon the acute performance and clinical data from the Resolute Onyx drug-eluting stent. The device is available in the entire Europe including Germany., March 2022: Cathi Distribution GmbH, a company specializing in endovascular simulators, launched the Cathis RHC 2, the company’s next-generation suitable heart catheter (RHC) simulator, in many countries of Europe, including the Netherlands.. Key drivers for this market are: Increasing Burden of Cardiovascular Diseases, Growing Preference for Minimally Invasive Procedures. Potential restraints include: Stringent Regulatory Policies and High Cost of Instruments and Procedures. Notable trends are: Catheter is Expected to Witness Growth Over the Forecast Period..

The Netherlands cardiovascular devices market, valued at €686.27 million in 2025, is projected to experience robust growth, driven by a rising geriatric population predisposed to cardiovascular diseases, increasing healthcare expenditure, and advancements in minimally invasive procedures. The market's Compound Annual Growth Rate (CAGR) of 5.58% from 2025 to 2033 indicates a significant expansion, with the market expected to surpass €1 billion by 2033. Key market segments include diagnostic and monitoring devices (ECG, remote cardiac monitoring) and therapeutic and surgical devices (cardiac assist devices, pacemakers, catheters). The strong presence of multinational corporations like Abbott Laboratories, Boston Scientific, Medtronic, and Philips Healthcare in the Netherlands contributes to the market's dynamism and technological advancement. Increased government initiatives focused on improving cardiovascular health outcomes further fuel market growth. However, high device costs and stringent regulatory approvals could pose challenges to market expansion. The growth is expected to be particularly strong in the therapeutic and surgical devices segment due to the increasing prevalence of heart failure and other conditions requiring interventional procedures. Technological innovations such as AI-powered diagnostic tools and implantable devices with improved longevity will further shape the market landscape. Competition is intense, with established players and emerging companies vying for market share through product innovation and strategic partnerships. The market’s growth trajectory is influenced by several factors. The aging population, as mentioned earlier, is a primary driver. Furthermore, increased awareness of cardiovascular diseases and improved healthcare infrastructure in the Netherlands are contributing to better diagnosis and treatment rates. The rising prevalence of lifestyle-related risk factors such as obesity, smoking, and diabetes also significantly contributes to the growth. While regulatory hurdles exist, the Netherlands' well-developed healthcare system and strong regulatory framework ensure a conducive environment for market growth, attracting further investment and innovation. The market is expected to witness continuous adoption of advanced technologies, leading to a shift towards minimally invasive procedures and improved patient outcomes. This positive trend is expected to enhance the market's expansion over the forecast period. Recent developments include: August 2022: Medtronic launched a drug-eluting coronary stent, the Onyx Frontierdrug-eluting stent (DES), following recent CE Mark approval. The Onyx Frontier DES offers an innovative delivery system and builds upon the acute performance and clinical data from the Resolute Onyx drug-eluting stent. The device is available in the entire Europe including Germany., March 2022: Cathi Distribution GmbH, a company specializing in endovascular simulators, launched the Cathis RHC 2, the company’s next-generation suitable heart catheter (RHC) simulator, in many countries of Europe, including the Netherlands.. Key drivers for this market are: Increasing Burden of Cardiovascular Diseases, Growing Preference for Minimally Invasive Procedures. Potential restraints include: Increasing Burden of Cardiovascular Diseases, Growing Preference for Minimally Invasive Procedures. Notable trends are: Catheter is Expected to Witness Growth Over the Forecast Period..

In Europe Cardiovascular Surgery Devices Market, The demand is driven by several key factors, including the rising prevalence of cardiovascular diseases (CVDs), advancements in surgical techniques, and increasing demand for minimally invasive procedures:

The Cardiac Assist Devices Market is estimated to be worth USD 1.4 Billion in 2025 and is expected to grow to USD 2.5 Billion by 2035, with a CAGR of 5.8% during the forecast period.

Market Metrics	Value
Market Size (2025E)	USD 1.4 Billion
Market Value (2035F)	USD 2.5 Billion
CAGR (2025 to 2035)	5.8%

Country-wise Analysis

Country	CAGR (2025 to 2035)
USA	6.1%

Country	CAGR (2025 to 2035)
UK	5.7%

Country	CAGR (2025 to 2035)
European Union (EU)	5.8%

Country	CAGR (2025 to 2035)
Japan	6.0%

Country	CAGR (2025 to 2035)
South Korea	6.1%

Competitive Outlook

Company Name	Estimated Market Share (%)
Abiomed, Inc. (Johnson & Johnson MedTech)	15-20%
Medtronic plc	12-17%
Abbott Laboratories	10-14%
Berlin Heart GmbH	7-11%
Getinge AB (Maquet Cardiovascular)	5-9%
Other Companies (combined)	40-50%

The Europe Cardiac Rhythm Management Devices Market size was valued at USD 4779.45 Million in 2024 and is projected to reach USD 7739.29 Million by 2032, growing at a CAGR of 6.21% from 2026 to 2032.

Key Market Drivers

• Increasing Prevalence of Cardiovascular Diseases: The increasing prevalence of cardiovascular illnesses in the European population is a major driver of cardiac rhythm management devices. According to the European Heart Network’s 2022 report, cardiovascular illnesses are still the largest cause of mortality in Europe, accounting for 35% of all fatalities, with an estimated 13 million new instances of cardiovascular disease diagnosed each year. Because of this high illness burden, advanced cardiac rhythm management technologies are critical for improving patient monitoring, diagnosis, and therapy.

• Aging Population: The aging population in Europe is considerably contributing to the expansion of the cardiac rhythm management device market. Eurostat data from 2021 show that 20.8% of the European population is already 65 or older, with estimates indicating that this figure will rise to 29.5% by 2050.

The Europe Cardiac Assist Devices Market is Segmented by Product (Intra-aortic Balloon Pump, Total Artificial Heart, and Ventricular Assist Device), and Geography (Germany, UK, France, Italy, Spain, and Rest of Europe). The report offers the value (in USD million) for the above segments.

The Eastern Europe Cardiac Arrhythmia Monitoring Devices report provides a detailed analysis of emerging investment pockets, highlighting current and future market trends. It offers strategic insights into capital flows and market shifts, guiding investors toward growth opportunities in key industry segments and regions.